Biotech/Pharma Stocks To Watch In The First Days Of February
The final week of January was yet another big one for biotech, with perhaps the most important development of the week being phase III trial results for Novavax’s COVID-19 vaccine.
Stocks
Why Now Is The Time To Invest In The Genomic Revolution – And A Highly Specialized Play To Do Just That
The genomic revolution in underway, with the author of today’s article noting that “artificial intelligence is converging with decades of breakthrough genomics research to create a new generation of hyper-efficient, hyper-accurate, and hyper-precise gene editing medicines.”
Is Novavax A Buy Right Now? A Look At The Stock And Its Coronavirus Vaccine Candidate
Over the course of the past 12 months, Novavax has gone from penny stock status before the pandemic to skyrocketing more than 2,700% over the course of the pandemic thus far.
Insights On Genomics, Electric Vehicles, Blockchain And More From The Top Stock Picker Of 2020
2020 Top Stock Picker shares insights on the outlook for genomics, electric vehicles, blockchain technology and more.
Small- And Mid-Cap Biotech Picks For 2021
Small- And Mid-Cap Biotech Picks For 2021 and holdovers from 2020.
How To Capitalize On What Could Be “The Best Decade, Ever, For The Stock Market”
Now, as 2021 begins, the author of today’s article believes that the “next decade could easily be the best decade, ever, for the stock market as post-war euphoria and easy money policy couple with multiple hypergrowth technological breakthroughs to rapidly unlock tremendous and widespread economic value.”
Why Individual Stock Selection Will Be Key For Biotech Investors In 2021 – And RBC’s 15 Top Ideas
When it comes to biotech investing in 2021, healthcare stock analysts at RBC advised in a recent report that “Many pandemic-related influences are setting up the sector for outperformance but several factors could still work against the group, making individual stock selection a key priority…”
Promising Test Results For Its Cancer Drugs Just Launched This Small Biotech To A Record High
On Monday, the small biotech stock highlighted in today’s article hit a record high, skyrocketing 95.1%. The catalyst?
5 Aggressive Tech Plays Under $10
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential,” declares the author of today’s… Read More »5 Aggressive Tech Plays Under $10
Upside Potential Over 100% Have Analysts “Pounding The Table” On These 3 Stocks
Among the three stocks highlighted in today’s article where analysts at RBC see upside potential over 100% – and which have all earned “Strong Buy” consensus analyst ratings – is “a pharmaceutical company with a unique niche.